Preclinical models demonstrated that PE-CSLT modulates AMPK/SREBP1/ACACA/PPARa signaling to attenuate hepatic steatosis and dyslipidemia, providing mechanistic support for its therapeutic potential. This evidence concerns the gene SREBF1 and metabolic syndrome.